Skip to content

Pre-meal Protein Drink Improve Glycemic Regulation

Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01987674
Acronym
PMB/T2D
Enrollment
35
Registered
2013-11-19
Start date
2014-01-31
Completion date
2015-07-31
Last updated
2016-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The purpose of this study is to investigate if a pre-meal drink containing proteins can positively influence glycaemic control in patients with type 2 diabetes mellitus. Comparison with a placebo is included.

Interventions

DIETARY_SUPPLEMENTPre-meal protein drink
OTHERWater drink

Sponsors

Landstinget i Kalmar Län
CollaboratorOTHER
Lund University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosed type 2 diabetes mellitus according to WHO criteria (1999) * age between 30-80 years * non well controlled diabetes with HbA1c-levels above 62 mmol/mol

Exclusion criteria

* pregnant or risk of becoming pregnant * severe disease * psychological disease, dementia or mental disability that makes it impossible to retrieve informed consent of participation * liver disease * kidney malfunction (GFR \<60 or aspartate transaminase (ASAT)/alanine transaminase (ALT) two times higher than the normal interval

Design outcomes

Primary

MeasureTime frameDescription
HbA1c16 weeksGlycated hemoglobin

Secondary

MeasureTime frameDescription
Postprandial glycemia16 weeksMeal challenge given at start and end of study with repeated blood glucose sampling over 2h.

Other

MeasureTime frameDescription
Homeostasis model assessment of insulin resistance (HOMA-IR)16 weeksHOMA-IR is a mathematical modelling of insulin resistance using fasting values of blood glucose and serum insulin.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026